|
|
Note:
|
A lot has happened in the CAR-T field in the past 10 months since our last conference report on this technology. These include high-impact news such as EMA approval, and NICE recommendations for Kymriah and Yescarta.
As the ASCO 2019 Annual Meeting is less than a month away, we are publishing an updated CAR-T clinical landscape report. This year, in addition to updating the industry funded CAR-T pipeline, we have included non-industry funded CAR-Ts, as well. We believe this addition will give you a better picture of the current CAR-T clinical landscape. To keep the scope manageable, we have limited our research to only those CAR-Ts that are conducted in US and/or EU location(s).
We hope this report will help you get up to speed before the upcoming ASCO 2019 Annual Meeting.
As the ASCO 2019 Annual Meeting is less than a month away, we are publishing an updated CAR-T clinical landscape report. This year, in addition to updating the industry funded CAR-T pipeline, we have included non-industry funded CAR-Ts, as well. We believe this addition will give you a better picture of the current CAR-T clinical landscape. To keep the scope manageable, we have limited our research to only those CAR-Ts that are conducted in US and/or EU location(s).
We hope this report will help you get up to speed before the upcoming ASCO 2019 Annual Meeting.
Research Boundary and Caveats
57 CAR-Ts are under investigation by 27 companies*
*Only results from Industry-funded trials are presented here
| CAR-T Pipeline Landscape - Overall |
In total, there are 22 CAR-Ts under clinical development for Solid cancers*
*Only results from Industry-funded trials are presented here
| CAR-T Landscape - Solid Malignancies |
|
Are you seeking a comprehensive assessment of combination strategies and rationale behind each? Are you looking for an experienced research agency to decide which indication to prioritize for your preclinical/clinical assets?
Oncofocus has years of experience in providing solutions across product lifecycle. Engage Us! |